Dopamin-D2-Rezeptorszintigraphie mit ¹²³I-Jodbenzofuran beim malignen Melanom

Zusammenfassung

In jüngsten Publikationen wurde die Dopamin-D2-Rezeptorszintigraphie mit Benz-amiden zur spezifischen Darstellung von Melanomen vorgeschlagen. In einer prospektiven Studie wurde die Wertigkeit von ¹²³I-Jodbenzofuran (IBF), einem hochspezifischen und hochaffinen Dopamin-D2-Rezeptorliganden zum Nachweis von Melanommetastasen untersucht. Mit der IBF-D2-Rezeptorszintigraphie ließen sich nur 2 von 17 Melanommetastasen nachweisen. Die Beurteilung des Abdomens war durch die hepatobiliäre Ausscheidung des Radionuklids stark eingeschränkt. Der Quotient Striatum/Frontalhirn von 2,75 ± 0,49 3 h p.i. belegte die hohe D2-Rezeptorbindung des Liganden. Die IBF-D2-Rezeptorszintigraphie ist als Staginguntersuchung beim Melanom nicht geeignet.

Summary

In recent publications dopamine-D2 receptor scintigraphy with benzamides was postulated for specific imaging of melanoma. In a prospective study the value of ¹²³I-iodobenzofuran (IBF), a highly specific and affine dopamine-D2 receptor ligand was evaluated for the detection of melanoma metastases. With IBF-D2 receptor scintigraphy only 2 of 17 melanoma metastases could be detected. The interpretation of the abdomen was impaired by the hepatobiliary and renal excretion of the radionuclide. The ratio striatum/frontal cortex of 2,75 ± 0,49 3 h p.i. demonstrated a high D2-receptor binding of the ligand. IBF-D2-receptor scintigraphy is not suitable as a method of staging melanoma.

Schlüsselwörter

Melanom - Dopamin-D2-Rezeptoren - Jodbenzofuran - ¹²³I-IBF

Key words

Melanoma - dopamine-D2 receptors - iodobenzofuran - ¹²³I-IBF

• Literatur

• 1 Agui T, Byrant G, Kebabian W. et al. ¹²⁵I-iodinated benzazepines bind to melanin: implications for the noninvasive localization of pigmented melanomas. Nucl Med Biol 1987; 14: 133-41.
• 2 Billings J, Guo YZ, Kung MP, Kung HF. Localization of IBF as a dopamine receptor imaging agent in nonhuman primates. Eur J Nucl Med 1993; 20: 1146-53.
• 3 Bockisch A, Oehr P, Biltz H. et al. The clinical value of radioimmunodetection (RID) using anti-melanoma antibodies. Tumordiag Ther 1991; 12: 112-6.
• 4 Brandau W, Kirchner B, Bartenstein P. et al. N-(2-diethylaminoethyl)-4-¹²³I-iodobenzamide as a tracer for the detection of malignant melanoma: simple synthesis, improved labelling technique and first clinical results. Eur J Nucl Med 1993; 20: 238-43.
• 5 Brozena SJ, Fenske NA, Perez IR. Epidemiology of malignant melanoma, worldwide incidence, and etiologic factors. Sem Surg Oncol 1993; 9: 165-7.
• 6 Brücke T, Podreka I, Angelberger P. et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metabol 1991; 11: 220-8.
• 7 Buck A, Westera G, Kung HF. et al. SPECT imaging with the new D2 ligand [I-123]IBF, comparison with [I-123]IBZM. Eur J Nucl Med 1993; 20: 857.
• 8 Chluba De Tapia J, Eberle AN. Dopamine receptor mRNA in B₁₆ mouse melanoma cells. Ann New York Acad Sei 1993; 660-2.
• 9 Cohen MB, Saxton RE, Lake RR. et al. Detection of malignant melanoma with iodine-123 iodoamphetamine. J Nucl Med 1988; 29: 1200-6.
• 10 Hoefnagel CA, Rankin EM, Valdes Olmos RA. et al. Sensitivity versus specificity in melanoma using iodine-123 iodobenzamide and indium-Ill pentetreotide. Eur J Nucl Med 1994; 21: 587-8.
• 11 Ishiwata K, Kubota K, Kubota R. et al. Selective 2-¹⁸F-fluorodopa uptake for melano-genesis in murine metastatic melanomas. J Nucl Med 1991; 32: 95-101.
• 12 John CS, Bowen WD, Saga T. et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylami-noethyl)4-iodobenzamide. J Nucl Med 1993; 34: 2169-75.
• 13 Kirkwood JM, Myers JE, Vlock DR. et al. Tomographic Gallium-67 citrate scanning: Useful new surveillance for metastatic melanoma. Ann Intern Med 1982; 97: 694-9.
• 14 Kloster G, Bockslaff H. L-3¹²³I-alpha-me-thyltyrosine for melanoma detection: a comparative evaluation. Int J Nucl Med Biol 1982; 9: 259-69.
• 15 Lakhani S, Selby P, Bliss JM. et al. Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer 1990; 61: 330-4.
• 16 Langevelde van A, Bakker CNM, Boer H. et al. Potential radiopharmaceuticals for the detection of ocular melanoma. Iodoquino-line derivatives and ⁶⁷Ga-citrate. Eur J Nucl Med 1986; 12: 96-104.
• 17 Langevelde van A, Bergmann W, Fetsma RIJ, Osanto S, Pauwels EKJ. A patient study with radioiodione labelled 5-iodo-2-thioura-dJ. Eur J Nucl Med 1988; 14: 640-1.
• 18 Maffioli L, Mascheroni L, Monioj V. et al. Scintigraphic detection of melanoma metastasis with a radiolabeled benzamide (1-123-(S)-IBZM). J Nucl Med 1994; 35: 1741-7.
• 19 Michelot JM, Moreau MFC, Labarre PG. et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991; 32: 1573-80.
• 20 Michelot JM, Moreau MFC, Veyre AJ. et al. Phase II scintigraphic clinical trial of malignant melanoma and metastasis with iodine-123-N-(2-diethylaminoethyl 4-iodobenza-mide). J Nucl Med 1993; 34: 1260-6.
• 21 Steinert H, Huch Boni RA, Buck A. et al. Malignant melanoma: staging with whole-body positron emission tomography and ¹⁸F-fluorodeoxy-glucose. Radiology 1995; 195: 705-9.
• 22 Tatsch K, Schwarz WH, Oertel WH, Kirsch CM. Idiopathic Parkinson syndrome: 1-123 IBZM SPECT findings in drug naive and treated patients. Eur J Nucl Med 1992; 19: 609.
• 23 Westera G, Kung HF, Buck A, von Schulthess GK. A simplified preparation and metabolite analysis of a new D2-SPECT ligand: ¹²³I-IBF. J Labelled Comp Radio-pharm 1994; 25: 469-70.